Robust Risk Management Plans, a Key to Improving Pharmacovigilance Standards in Asia

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.

The pharma industry in Asia faces a challenge: a lack of standardisation in risk management planning is playing havoc with attempts to improve drug safety. Many nations in the Asia region are implementing their own national risk management schemes, but a lack of harmony between reporting threatens the collection of reports between countries.

Read about these and other challenges plus how the industry is confronting in its attempts to create a safer, more intelligent pharmacovigilance environment in Asia